Aevi Genomic Medicine, Inc. (GNMX) financial statements (2022 and earlier)

Company profile

Business Address 435 DEVON PARK DRIVE,
WAYNE, PA 19087
State of Incorp. DE
Fiscal Year End December 31
SIC 2836 - Biological Products, Except Diagnostic Substances (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in thousands)

9/30/2019
Q3
6/30/2019
Q2
3/31/2019
Q1
12/31/2018
Q4
9/30/2018
Q3
6/30/2018
Q2
3/31/2018
Q1
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments2,3813,4376,94812,07619,60219,15126,520
Cash and cash equivalents2,3813,4376,94812,07619,60219,15126,520
Other undisclosed current assets403572650170538855801
Total current assets:2,7844,0097,59812,24620,14020,00627,321
Noncurrent Assets
Property, plant and equipment11420365369
Restricted cash and investments11111111111111
Other noncurrent assets     16333
Other undisclosed noncurrent assets  11    
Total noncurrent assets:1212263147227113
TOTAL ASSETS:2,7964,0217,62412,27720,18720,23327,434
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities, including:1233027362,7631,5851,4631,685
Accounts payable1233027361,5821,5851,4631,685
Employee-related liabilities   47   
Other undisclosed accounts payable and accrued liabilities   1,134   
Other undisclosed current liabilities4,1303,3873,1671,5824,8503,4803,054
Total current liabilities:4,2533,6893,9034,3456,4354,9434,739
Noncurrent Liabilities
Liabilities, other than long-term debt2,000      
Due to related parties2,000      
Total noncurrent liabilities:2,000      
Total liabilities:6,2533,6893,9034,3456,4354,9434,739
Stockholders' equity
Stockholders' equity attributable to parent(3,457)3323,7217,93213,75215,29022,695
Common stock7777666
Additional paid in capital254,815254,562254,306253,678252,873247,162246,376
Accumulated deficit(258,279)(254,237)(250,592)(245,753)(239,127)(231,878)(223,687)
Total stockholders' equity:(3,457)3323,7217,93213,75215,29022,695
TOTAL LIABILITIES AND EQUITY:2,7964,0217,62412,27720,18720,23327,434

Income statement (P&L) ($ in thousands)

9/30/2019
Q3
6/30/2019
Q2
3/31/2019
Q1
12/31/2018
Q4
9/30/2018
Q3
6/30/2018
Q2
3/31/2018
Q1
Operating expenses(4,042)(1,415)(1,685)(1,811)(2,174)(2,504)(2,174)
Other undisclosed operating loss (2,234)(3,169)(4,866)(5,125)(5,747)(6,561)
Operating loss:(4,042)(3,649)(4,854)(6,677)(7,299)(8,251)(8,735)
Nonoperating income
(Other Nonoperating income)
 41551506026
Net loss available to common stockholders, diluted:(4,042)(3,645)(4,839)(6,626)(7,249)(8,191)(8,709)

Comprehensive Income ($ in thousands)

9/30/2019
Q3
6/30/2019
Q2
3/31/2019
Q1
12/31/2018
Q4
9/30/2018
Q3
6/30/2018
Q2
3/31/2018
Q1
Net loss:(4,042)(3,645)(4,839)(6,626)(7,249)(8,191)(8,709)
Comprehensive loss, net of tax, attributable to parent:(4,042)(3,645)(4,839)(6,626)(7,249)(8,191)(8,709)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: